Lifeboat Foundation

Rates increased among all age groups, including newborns, and in all regions of the country. In 2022, 3,755 cases of babies born with syphilis in the U.S. were reported, which reflects an alarming 937% increase in the past decade, the CDC said.

The report continued that racial and ethnic minorities are most disproportionately affected due to “long standing social inequities that often lead to health inequalities.”

Combined, infection, autoimmunity and cancer account for 4 out of every 10 deaths worldwide, and represent major global health challenges. In a paper in the journal Cell Reports, Institute for Systems Biology (ISB) researchers highlight a novel discovery of how the human immune system works in common ways across diseases, and offer promising avenues for exploring multi-disease therapeutic strategies.

Many therapies, while effective for one class of disease, may aggravate others. Cancer treatments like immune checkpoint blockade, for example, can trigger autoimmunity. Similarly, drugs targeting autoimmune diseases may leave patients more susceptible to infections and cancer.

Continue reading “Common immune response is found to be protective across many diseases” »

Cervical cancer, which develops in the lower portion of the uterus, known as the cervix, typically grows slowly. Cells in the cervix can change, a process known as dysplasia, and the resulting abnormal cells, if not removed, can develop into cervical cancer.

When cervical cancer occurs, treatment options vary based on many factors, including how far the disease has advanced and the overall health of the patient. Some cervical cancer patients may undergo a simple hysterectomy (also known as a complete or total hysterectomy). A simple hysterectomy removes the uterus and cervix.

The perimetrium, fat and connective tissue around the uterus, connects the uterus to the cervix and other tissues. Some patients with cervical cancer experience “parametrial invasion” (also referred to as parametrial infiltration), during which cervical cancer has spread into the parametrial tissue.

The elevated cardiovascular disease risk among people with HIV is even greater than predicted by a standard risk calculator in several groups, including Black people and cisgender women, according to analyses from a large international clinical trial primarily funded by the National institutes of Health and presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver. The risk of having a first major cardiovascular event was also higher than previously predicted for people from high-income regions and those whose HIV replication was not suppressed below detectable levels.

Researchers examined the incidence of major adverse cardiovascular events in people who did not take pitavastatin or other statins during the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial, a large clinical trial to test whether pitavastatin—a cholesterol-lowering drug known to prevent cardiovascular disease—could prevent major adverse cardiovascular events, such as heart attacks and strokes, in people with HIV. The scientists compared the incidence of cardiovascular events in the trial to the incidence predicted by standard estimates, which use the American College of Cardiology and American Heart Association’s Pooled Cohort Risk Equations (PCE) score.

They found that the rate of cardiovascular events occurring in many groups of people differed from predicted rates, even considering that people with HIV have a higher overall risk of cardiovascular disease than people without HIV, including double the risk of major adverse cardiovascular events. Notably, in high-income regions—as defined by the global burden of disease classification system—including North and South America and Europe, cardiovascular event rates were higher overall, with cisgender women experiencing about two and a half times more events than predicted, and Black participants having more than 50% higher event rates than predicted.

NIH-supported study shows long-term benefits of surgery compared to medication and lifestyle change.

People with type 2 diabetes who underwent bariatric surgery achieved better long-term blood glucose control compared to people who received medical management plus lifestyle interventions, according to a new study supported by the National Institutes of Health. The participants who underwent bariatric surgery, also called metabolic or weight-loss surgery, were also more likely to stop needing diabetes medications and had higher rates of diabetes remission up to 12 years post-surgery. Results of the study were published in JAMA and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of NIH.

“While there are many factors involved, and not all of them are completely understood, bariatric surgery typically results in greater weight loss that affects a person’s metabolic hormones, which improves the body’s response to insulin and ability to maintain healthy blood glucose levels,” said Dr. Jean Lawrence, NIDDK project scientist. “These results show that people with overweight or obesity and type 2 diabetes can make long-term improvements in their health and change the trajectory of their diabetes through surgery.”

https://www.youtube.com/watch?app=desktop&v=qn8ahPBFVSs

Here Dr Tan introduces geranylgeraniol (GG), talks about its discovery and its importance in human metabolism.

Wellness Extract 5% discount Code MODERN10
GG Essential https://collabs.shop/ivoshz.
Vitamin E, Delta Gold https://collabs.shop/gfjyof.
Bio Quinol with GG https://collabs.shop/wm9cce.
Renue By Science 10% : Code MHS https://tinyurl.com/35jyuk33
CoQ10 https://bit.ly/4bX3I6P\r.
ProHealth 15% discount Code MODERN: https://prohealth.pxf.io/Vm9BoA
CoQ10 https://prohealth.pxf.io/LX12N0
DoNotAge 10% discount code MHS https://tinyurl.com/6dbvhv87
Pure NMN https://tinyurl.com/wyzj2f3d.
Nuchido Time+ 20% discount of first purchase with code MODERN20 https://nuchido.com/MODERN
NOVOS https://novos.sjv.io/QyWP7o code 5OFFMHS
NMN Bio 10% off all products https://tinyurl.com/2af2v2fw Code ModernHealthSpan10 in link.
☕If you would like to support our channel, we’d love a coffee…thank you! https://www.buymeacoffee.com/mhealthspan.

Continue reading “A Promising Novel Anti-Aging Compound GG — Geranylgeraniol Explained By It Discoverer Dr Barrie Tan” »

Scientists from the University of Rochester have developed new electrochemical approaches to clean up pollution from “forever chemicals” found in clothing, food packaging, firefighting foams, and a wide array of other products. A new Journal of Catalysis study describes nanocatalysts developed to remediate per-and polyfluoroalkyl substances known as PFAS.

The researchers, led by assistant professor of chemical engineering Astrid Müller, focused on a specific type of PFAS called Perfluorooctane sulfonate (PFOS), which was once widely used for stain-resistant products but is now banned in much of the world for its harm to human and animal health. PFOS is still widespread and persistent in the environment despite being phased out by US manufacturers in the early 2000s, continuing to show up in water supplies.

Researchers led by Northwestern University and Washington University School of Medicine in St. Louis have developed a new, first-of-its-kind sticker that enables clinicians to monitor the health of patients’ organs and deep tissues with a simple ultrasound device.

When attached to an organ, the soft, tiny sticker changes in shape in response to the body’s changing pH levels, which can serve as an early warning sign for post-surgery complications such as anastomotic leaks. Clinicians then can view these shape changes in real time through ultrasound imaging.

Currently, no existing methods can reliably and non-invasively detect anastomotic leaks—a life-threatening condition that occurs when gastrointestinal fluids escape the digestive system. By revealing the leakage of these fluids with high sensitivity and high specificity, the non-invasive sticker can enable earlier interventions than previously possible. Then, when the patient has fully recovered, the biocompatible, bioresorbable sticker simply dissolves away—bypassing the need for surgical extraction.

Scientists at the National Institutes of Health have discovered antibodies that attack a difficult-to-detect area of the influenza virus, shedding light on the relatively unexplored “dark side” of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many influenza viruses, including H3N2 subtype viruses, and could be a new target for countermeasures. The research, led by scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, part of NIH, was recently published in the journal Immunity.

Influenza, or flu, sickens millions of people across the globe each year and can lead to severe illness and death. While vaccination against influenza reduces the burden of the disease, updated vaccines are needed each season to provide protection against the many strains and subtypes of the rapidly evolving virus. Vaccines that provide protection against a broad range of influenza viruses could prevent outbreaks of new and reemerging flu viruses without the need for yearly vaccine reformulation or vaccinations.